CN112469721B - 三唑并嘧啶化合物和其用于治疗癌症的用途 - Google Patents

三唑并嘧啶化合物和其用于治疗癌症的用途 Download PDF

Info

Publication number
CN112469721B
CN112469721B CN201980046079.2A CN201980046079A CN112469721B CN 112469721 B CN112469721 B CN 112469721B CN 201980046079 A CN201980046079 A CN 201980046079A CN 112469721 B CN112469721 B CN 112469721B
Authority
CN
China
Prior art keywords
methyl
trimethyl
triazolo
pyrrolidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980046079.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112469721A (zh
Inventor
F·W·高德柏格
A·K·T·丁
G·M·拉蒙特
D·巴塔
J·G·柯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizhe Jiangsu Pharmaceutical Co ltd
Original Assignee
Dizhe Jiangsu Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizhe Jiangsu Pharmaceutical Co ltd filed Critical Dizhe Jiangsu Pharmaceutical Co ltd
Priority to CN202210528891.2A priority Critical patent/CN115028636A/zh
Priority to CN202210528893.1A priority patent/CN115028637B/zh
Publication of CN112469721A publication Critical patent/CN112469721A/zh
Application granted granted Critical
Publication of CN112469721B publication Critical patent/CN112469721B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980046079.2A 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途 Active CN112469721B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210528891.2A CN115028636A (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途
CN202210528893.1A CN115028637B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670075P 2018-05-11 2018-05-11
US62/670,075 2018-05-11
PCT/EP2019/062020 WO2019215316A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202210528891.2A Division CN115028636A (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途
CN202210528893.1A Division CN115028637B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途

Publications (2)

Publication Number Publication Date
CN112469721A CN112469721A (zh) 2021-03-09
CN112469721B true CN112469721B (zh) 2022-06-07

Family

ID=66484070

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980046079.2A Active CN112469721B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途
CN202210528893.1A Active CN115028637B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途
CN202210528891.2A Pending CN115028636A (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210528893.1A Active CN115028637B (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途
CN202210528891.2A Pending CN115028636A (zh) 2018-05-11 2019-05-10 三唑并嘧啶化合物和其用于治疗癌症的用途

Country Status (16)

Country Link
US (3) US11084827B2 (https=)
EP (2) EP4134368A1 (https=)
JP (1) JP7418353B2 (https=)
KR (1) KR102863374B1 (https=)
CN (3) CN112469721B (https=)
AR (1) AR115384A1 (https=)
AU (1) AU2019264826B2 (https=)
BR (1) BR112020023068A2 (https=)
CA (1) CA3099579A1 (https=)
DK (1) DK3790879T3 (https=)
ES (1) ES2927244T3 (https=)
MX (1) MX2020012058A (https=)
PT (1) PT3790879T (https=)
TW (1) TWI823932B (https=)
UY (1) UY38228A (https=)
WO (1) WO2019215316A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
WO2021174176A1 (en) * 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
US20230192704A1 (en) * 2020-05-21 2023-06-22 Teon Therapeutics, Inc. Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
WO2022090527A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
WO2022243573A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use
CN120699024A (zh) * 2024-03-25 2025-09-26 北京福元医药股份有限公司 Mct4抑制剂及其药物组合物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017196936A1 (en) * 2016-05-12 2017-11-16 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) * 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
DE102005034905A1 (de) 2005-07-26 2007-02-01 Federal-Mogul Nürnberg GmbH Verfahren zur Herstellung eines Kolbens für einen Verbrennungsmotor sowie Kolben für einen Verbrennungsmotor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
US10328078B2 (en) * 2015-01-22 2019-06-25 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
CA2974697A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters
BR112017026535B1 (pt) * 2015-06-12 2023-12-19 Vettore, LLC Composto e composição farmacêutica
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017196936A1 (en) * 2016-05-12 2017-11-16 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
BR112020023068A2 (pt) 2021-02-09
EP4134368A1 (en) 2023-02-15
EP3790879B1 (en) 2022-06-29
AR115384A1 (es) 2021-01-13
CN112469721A (zh) 2021-03-09
EP3790879A1 (en) 2021-03-17
ES2927244T3 (es) 2022-11-03
US20210087196A1 (en) 2021-03-25
CN115028636A (zh) 2022-09-09
WO2019215316A1 (en) 2019-11-14
PT3790879T (pt) 2022-08-26
AU2019264826A1 (en) 2020-11-26
CN115028637A (zh) 2022-09-09
US12503473B2 (en) 2025-12-23
CA3099579A1 (en) 2019-11-14
KR102863374B1 (ko) 2025-09-22
US11851432B2 (en) 2023-12-26
AU2019264826B2 (en) 2024-05-23
US11084827B2 (en) 2021-08-10
US20210340150A1 (en) 2021-11-04
KR20210013078A (ko) 2021-02-03
CN115028637B (zh) 2024-03-22
DK3790879T3 (da) 2022-08-29
US20240217980A1 (en) 2024-07-04
JP7418353B2 (ja) 2024-01-19
JP2021523177A (ja) 2021-09-02
TW202015674A (zh) 2020-05-01
TWI823932B (zh) 2023-12-01
MX2020012058A (es) 2021-02-26
UY38228A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
CN112469721B (zh) 三唑并嘧啶化合物和其用于治疗癌症的用途
CN111936498B (zh) N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
KR20220004100A (ko) 안드로겐 수용체를 표적 분해하는 이중 기능성의 키메라 헤테로 고리 화합물 및 이의 용도
CN114845711A (zh) Raf激酶的抑制剂
KR20240053589A (ko) 이중 기능성 키메라 헤테로 고리 화합물 및 이의 안드로겐 수용체 분해제로서의 용도
CN113348170A (zh) 联苯类衍生物抑制剂、其制备方法和应用
WO2023198209A1 (zh) 一种kif18a抑制剂及其用途
EP2867233A1 (en) 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
JP2023533003A (ja) ヘテロ環式免疫調節物質
HK40080417A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080418A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047024A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080417B (zh) 三唑并嘧啶化合物和其用於治疗癌症的用途
RU2793249C2 (ru) Триазолпиримидиновые соединения и их применение в лечении рака
CN115151551B (zh) 作为mcl-1抑制剂的大环吲哚衍生物
HK40088382A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047025B (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047025A (en) Triazolopyrimidine compounds and their use in treating cancer
TWI910148B (zh) 芳基或雜芳基衍生物
WO2026086879A1 (zh) Fak抑制剂
HK40049641A (en) Biphenyl derivative inhibitor, preparation method therefor and use
HK40077347A (zh) Raf激酶的抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40047024

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant